Delhi Delhi. Enlon Healthcare, a Rajkot-based research-focused pharmaceutical bulk drug and intermediate production corporate, has submitted revised draft papers to SEBI to boost price range thru an IPO, Moneycontrol reviews.
It had previous submitted IPO initial paperwork on October 9 and won a reaction from the capital markets regulator on December 9.
Recent DRHP finds the similar proposal
In step with the draft crimson herring prospectus filed on December 26, the chemical production corporate has saved its new factor measurement at 1.4 crore fairness stocks, with out a offer-for-sale part.
Use of IPO lawsuits
Of the web proceeds from the contemporary factor, the corporate will put aside Rs 30.7 crore to amplify its production facility, Rs 5 crore to pay off loans, Rs 35.98 crore to satisfy operating capital wishes and the remainder price range for normal company functions. Will use.
shareholding trend
Public shareholders comparable to Shree Dwarkadhis Ventures LLP, Amitaben Natwarlal Ukani and BAN Labs cling the remainder 29.74 in step with cent stake in Enlon, whilst promoters Puneetkumar Rasadia and Meet Atulkumar Vachani cling the remainder 70.26 in step with cent.
Indexed counterparties of the corporate
In comparison to indexed peer corporations like Cronox Lab Sciences, AMI Organics and Supriya Lifescience, Enlon is without doubt one of the few manufacturers of loxoprofen sodium dihydrate (in India), a notable API this is incessantly used to regard ache and irritation. Is.
Corporate’s product portfolio
Complicated pharmaceutical intermediates are produced via the corporate and used as uncooked fabrics to make lively pharmaceutical substances.
Moreover, the corporate produces APIs, that are used as number one substances in pharmaceutical formulations to create numerous ultimate dosage paperwork, together with drugs, pills, ointments, syrups and nutraceuticals, private care merchandise and Accommodates substances for animal well being merchandise.
#Enlon #Healthcare #recordsdata #revised #draft #papers #SEBI #carry #price range